Parexel purchases Taiwan firm

By Kirsty Barnes

- Last updated on GMT

Related tags Medicine Clinical trial

Parexel has purchased a clinical research organisation (CRO) in
Taiwan as a means to exert its presence in this industry's budding
Asia-Pacific region.

The buy, which cost Parexel roughly $50.9m, provides the firm with added access in China, Hong Kong, India, Taiwan, Singapore, Indonesia, South Korea, Malaysia, Thailand, the Philippines, New Zealand, and Australia where the acquired company, Apex, is currently active. Until now, Parexel owned a minority stake in Apex as it sought four years ago to dip its toes into the water before diving in. During this time the two firms worked together on several projects in the region until Parexel decided to take the relationship to the next level by gaining complete ownership. "The Asia-Pacific region is becoming increasingly important and attractive for a wide range of clinical development activities… We believe that the acquisition of Apex is of great strategic value,"​ said Josef von Rickenbach, chairman and CEO of Parexel, which already has a presence in Japan, India, and Australia. Specifically, the firm said the union brings it the ability to now offer good clinical practice (GCP)-compliant services, especially in late phases of clinical development, in the above-mentioned Asia-Pacific countries; along with clinical and regulatory experts with local experience; and medical expertise and access to patient populations across a wide range of complex and important therapeutic areas, including cardiology, rheumatology, endocrinology, oncology, infectious disease, and neurology. The global CRO will now operate under the new name of Parexel Apex International.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us